Search Result

Results for "

103N

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (1) DNA/RNA Synthesis (1) HIV (16) Isotope-Labeled Compounds (1) MMP (1) Reverse Transcriptase (5)
By Research Areas:	Infection (17) Inflammation/Immunology (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16767

Doravirine 5+ Cited Publications MK-1439	HIV Reverse Transcriptase	Infection
Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and *K103N* and Y181C reverse transcriptase mutants, respectively .

HY-W325699

HIV-1 inhibitor-48	HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-48 (compound 13o) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) and exhibits anti-HIV-1 activity .

HY-NP103

Highly purified Type III collagen, from bovine skin Bovine Type III collagen, immunization grade	MMP	Inflammation/Immunology
Highly purified Type III collagen, from bovine skin (Bovine Type III collagen, immunization grade) is an immune grade collagen derived from bovine skin, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .

HY-146365

HIV-1 inhibitor-30	HIV	Infection Inflammation/Immunology
HIV-1 inhibitor-30 (compound 10i) is a potent HIV-1 inhibitor with an EC₅₀ value of 40 nM and an IC₅₀ value of 80 nM for HIV-1 RT DNA polymerase. HIV-1 inhibitor-30 has highly antiretroviral activity against seven non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains (RT-K103N; RT-Y181C; RT-K103N,Y181C; RT-L100I,K103N; RT-Y188L; RT-K103N,G190A; RT-K103N,V108I) with IC₅₀s of 0.04~1.42 μM. HIV-1 inhibitor-30 can be used for researching AIDS .

HY-116528

GCA-186	HIV	Infection
GCA-186 is a potent anti-HIV-1 agent. GCA-186 is highly active against both wild type and mutated HIV-1 strains with EC₅₀s of 1, 180, 1, and 40 nM for III_B, III_B-R(Y181C), NL4-3 and NL4-3_K103N of HIV-1 strains, respectively .

HY-150599

HIV-1 inhibitor-43	HIV DNA/RNA Synthesis	Infection
HIV-1 inhibitor-43 is a potent HIV-1 inhibitor with an EC₅₀ of 21.3 nM, 6.2 nM, < 0.7 nM and < 0.7 nM for Y188L, K103N-Y181C, K103N and Y181C, respectively. HIV-1 inhibitor-43 can reduce HIV-1 RNA and protein p24 expression .

HY-111079

HIV-1 inhibitor-70	Others	Others
HIV-1 inhibitor-70 (compound 20) is a bifunctional inhibitor that inhibits both wild-type (WT) and K103N mutant reverse transcriptases (RTs) of HIV-1.

HY-146746

HIV-1 inhibitor-19	HIV	Infection
HIV-1 inhibitor-19 is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-19 maintains its inhibitory activity against L100I, K103N and V106A/ F227L mutant strains with EC₅₀s of 7.3 nM, 9.2 nM and 21.0 nM, respectively^[1].

HY-146018

HIV-1 inhibitor-23	HIV	Infection
HIV-1 inhibitor-23 (compound 12a) is a highly potent HIV-1 non-nucleoside reverse transcriptase inhibitor, with EC₅₀s of 24.9 nM and 10.4 nM for HIV-1 WT and HIV-1 K103N, respectively. HIV-1 inhibitor-23 has low cytotoxicity (CC₅₀ > 221 μM) and a favorable in vitro microsomal stability .

HY-16767S1

Doravirine-13C,d3 MK-1439-¹³C,d₃	Isotope-Labeled Compounds HIV Reverse Transcriptase	Infection
Doravirine-13C,d3 (MK-1439-13C,d3) is the deuterium labeled Doravirine (HY-16767). Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and *K103N* and Y181C reverse transcriptase mutants, respectively .

HY-130241

Reverse transcriptase-IN-1	HIV	Infection
Reverse transcriptase-IN-1 (Compound 12z), a diarylbenzopyrimidine (DABP) analogue, is a potent, orally active HIV-1 nonnucleoside reverse transcriptase inhibitor. Reverse transcriptase-IN-1 has antiviral activity with EC₅₀ values of 3.4 nM, 4.3 nM and 3.6 nM for HIV-1 III_B, E138K and *K103N* mutants, respectively. Reverse transcriptase-IN-1 also has an IC₅₀of 13.7 nM against HIV-1 reverse transcriptase enzyme .

HY-146017

HIV-1 inhibitor-22	HIV	Infection
HIV-1 inhibitor-22 (compound 11a) is a potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor, with an IC₅₀ value of 3.63 μM for HIV-1 RT. HIV-1 inhibitor-22 has antiretroviral activity against HIV-1 WT and K103N strains with EC₅₀s of 0.304 μM and 0.201 μM, also has low cytotoxicity (CC₅₀ > 227 μM)

HY-146015

HIV-1 inhibitor-21	HIV	Infection
HIV-1 inhibitor-21 (compound 9b) is a potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor, with an IC₅₀ value of 0.55 μM for HIV-1 RT. HIV-1 inhibitor-21 has antiretroviral activity against HIV-1 WT and K103N strains with EC₅₀s of 12.7 nM and 10.4 nM, and has relatively low cytotoxicity (MT-4 cells CC₅₀ =10.2 μM) .

HY-144122

HIV-1 inhibitor-15	HIV	Infection
HIV-1 inhibitor-15 (compound 9d) is a highly potent and broad-spectrum HIV-1 inhibitor. HIV-1 inhibitor-15 has inhibitory activity against HIV-1 WT, L100I, K103N, Y181C, E138K with EC₅₀s of 1.7 nM, 4 nM, 2 nM, 6 nM and 9 nM, respectively. HIV-1 inhibitor-15 has good solubility, safety profiles and favorable oral bioavailability .

HY-144123

HIV-1 inhibitor-16	HIV	Infection
HIV-1 inhibitor-16 (compound 7a) is a highly potent HIV-1 inhibitor with an EC₅₀ value of 1.3 nM for HIV-1 WT. HIV-1 inhibitor-16 also has certain inhibitory activity against HIV-1 K103N, E138K, Y181C and L100I strains with EC₅₀s of 5.4 nM, 9.2 nM, 22 nM and 35 nM. HIV-1 inhibitor-16 has favorable solubility and liver microsome stability, and does not exhibit apparent CYP enzymatic inhibitory activity or acute toxicity .

HY-149866

HIV-1 inhibitor-58	Cytochrome P450 HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-58 (Compound 10c) is a broad-spectrum antiviral agent. HIV-1 inhibitor-58 is a non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-58 inhibits WT strain IIIB, NNRTI-resistant strains (such as K103N and E138K) in MT-4 cells, with EC₅₀ less than 50 nM. HIV-1 inhibitor-58 also inhibits CYP2C9 and CYP2C19 (IC₅₀: 2.06 μM, 1.91 μM). HIV-1 inhibitor-58 can be used for HIV infection reserch .

HY-152161

HIV-1 inhibitor-51	HIV Reverse Transcriptase	Infection
HIV-1 inhibitor-51, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exhibits outstanding antiviral activity against WT HIV-1 (IIIB) and a panel of mutant strains. HIV-1 inhibitor-51 has high binding affinity (K_D=2.50 μM) and inhibitory activity (IC₅₀=0.03 μM) to WT HIV-1 RT. HIV-1 inhibitor-51 has EC₅₀s of 2.22-53.3 nM for mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L + V106A, RES056) .

HY-146019A

HIV-1 inhibitor-25	HIV	Infection
HIV-1 inhibitor-25 (compound R-12a) is a highly potent HIV-1 reverse transcriptase, with an IC₅₀ value of 0.1061 μM. HIV-1 inhibitor-25 has high antiretroviral activity against WT HIV-1 with an EC₅₀ of 13.6 nM, and exhibits relatively low cytotoxicity with a CC₅₀ of 33.13 μM in MT-4 cells. HIV-1 inhibitor-25 also has inhibitory activity against HIV-1 mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L+V106A) with EC₅₀ of 0.1961 ~ 5.8136 μM. HIV-1 inhibitor-25 can be used for researching AIDS .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library	1,725 compounds
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,725 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Anti-Colorectal Cancer Compound Library

1,725 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,725 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-NP103

Highly purified Type III collagen, from bovine skin Bovine Type III collagen, immunization grade	Native Proteins
Highly purified Type III collagen, from bovine skin (Bovine Type III collagen, immunization grade) is an immune grade collagen derived from bovine skin, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .

Cat. No.	Product Name	Chemical Structure

HY-16767S1

Doravirine-13C,d3
Doravirine-13C,d3 (MK-1439-13C,d3) is the deuterium labeled Doravirine (HY-16767). Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and *K103N* and Y181C reverse transcriptase mutants, respectively .

Cat. No.	Product Name		Classification

HY-167690

MK-6186		Alkynes
MK-6186 is a novel non-nucleoside reverse transcriptase inhibitor with sub-nanomolar activity against wild-type viruses and the two most common NNRTI-resistant RT mutants (K103N and Y181C). MK-6186 exhibits excellent antiviral activity against K103N and Y181C mutant viruses. When MK-6186 targets 12 common NNRTI-associated mutant viruses, only two relatively rare mutants (Y188L and V106I/Y188L) show high resistance, with FC values exceeding 100, while the FC values of the remaining viruses are all below 10. In addition, when MK-6186 faces 96 clinical virus isolates carrying NNRTI-resistant mutations, most (70%) viruses show more than 10-fold resistance to efavirenz (EFV), while only 29% of mutant viruses show more than 10-fold resistance to MK-6186 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.